The prevalence of obesity in nonvalvular atrial fibrillation (NVAF) patients is apparent in trials and realworld studies; however, there is limited data on the effectiveness and safety of anticoagulation specific to this population. This study evaluated stroke/systemic embolism (SE) and major bleeding (MB) among obese NVAF patients using non-VKA oral anticoagulants (NOACs) vs warfarin in the ARISTOPHANES (Anticoagulants for Reduction In STroke: Observational Pooled analysis on Health outcomes ANd Experience of patientS) study population.
